ReviewWorld journal of gastroenterology2014
Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03402334 (Assessing Healthcare Outcomes of Hepatitis C Virus), which is not on this map. Cited by 71 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessing Healthcare Outcomes of Hepatitis C Virus (HCV) Positive Patients Counseled for Cardiovascular Disease Risk Factors
Who cites it
71 citing papers in PubMed, 5 syntheses or guidelines pooled it, 172 citations in OpenAlex.
- The association between homocysteine and ischemic stroke subtypes in Chinese: A meta-analysis.Medicine · 2020Pooled it
- Guideline
- Maternal HCV infection is associated with intrauterine fetal growth disturbance: A meta-analysis of observational studies.Medicine · 2016Pooled it
- Elevated Serum Homocysteine (Hcy) Levels May Contribute to the Pathogenesis of Cerebral Infarction.Journal of molecular neuroscience : MN · 2015Pooled it
- Is hepatitis C associated with atherosclerotic burden? A systematic review and meta-analysis.PloS one · 2014Pooled it
- Trial
- Stroke in HIV-infected individuals with and without HCV coinfection in Spain in the combination antiretroviral therapy era.PloS one · 2017Trial
- SGLT2 Inhibitor Use and Cardiorenal Outcomes in Type 2 Diabetes With Liver Cirrhosis.JAMA network open · 2026Article
- Therapeutic, preventive, and pathogenetic advances in viral hepatitis.Frontiers in cellular and infection microbiology · 2026Review
- Chronic hepatitis C and the risk for atherosclerotic and cardiomyopathic heart disease.World journal of hepatology · 2025Review
- Do oxidized low-density lipoproteins link to extra hepatic manifestations in chronic, non-cirrhotic HCV patients?Metabolism open · 2025Article
- Comprehensive metagenomic and lipidomic analysis showed that baicalin could improve depressive behaviour in atherosclerotic mice by inhibiting nerve cell ferroptosis.Frontiers in immunology · 2025Article
- Extrahepatic Cancer Risk in Patients with Hepatitis C Virus Infection Treated with Direct-Acting Antivirals.Microorganisms · 2024Review
- Viral Infection and Ischemic Stroke: Emerging Trends and Mechanistic Insights.Journal of the American Heart Association · 2024Review
- Pro-atherogenic medical conditions are associated with widespread regional brain metabolite abnormalities in those with alcohol use disorder.Alcohol and alcoholism (Oxford, Oxfordshire) · 2024Article
- Independent Associations of Aortic Calcification with Cirrhosis and Liver Related Mortality in Veterans with Chronic Liver Disease.Digestive diseases and sciences · 2024Article
- Lipid Profile and Cardiovascular Risk Modification after Hepatitis C Virus Eradication.Pathogens (Basel, Switzerland) · 2024Review
- Article
- Cardioprotective effect of antiviral therapy among hepatitis C infected patients: A meta-analysis.International journal of cardiology. Heart & vasculature · 2023Article
- PHEVIR: an artificial intelligence algorithm that predicts the molecular role of pathogens in complex human diseases.Scientific reports · 2022Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) infection represents a major health issue worldwide due to its burden of chronic liver disease and extrahepatic manifestations including cardiovascular diseases, which are associated with excess mortality. Analysis of published studies supports the view that HCV infection should be considered a risk factor for the development of carotid atherosclerosis, heart failure and stroke. In contrast, findings from studies addressing coronary artery disease and HCV have yielded conflicting results. Therefore, meta-analytic reviews and prospective studies are warranted. The pathogenic mechanisms connecting HCV infection, chronic liver disease, and atherogenesis are not completely understood. However, it has been hypothesized that HCV may promote atherogenesis and its complications through several direct and indirect biological mechanisms involving HCV colonization and replication within arterial walls, liver steatosis and fibrosis, enhanced and imbalanced secretion of inflammatory cytokines, oxidative stress, endotoxemia, mixed cryoglobulinemia, perturbed cellular and humoral immunity, hyperhomocysteinemia, hypo-adiponectinaemia, insulin resistance, type 2 diabetes and other components of the metabolic syndrome. Understanding these complex mechanisms is of fundamental importance for the development of novel therapeutic approaches to prevent and to treat vascular complications in patients with chronic HCV infection. Currently, it seems that HCV clearance by interferon and ribavirin treatment significantly reduces non-liver-related mortality; moreover, interferon-based treatment appears to decrease the risk of ischemic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.